01 / DESIGN
What was studied?
This randomized study followed 611 adults without diabetes for 68 weeks. Both groups received intensive behavioral therapy and an initial low-calorie diet.
02 / FINDINGS
What did the researchers report?
Semaglutide produced greater average weight reduction than placebo alongside that shared intervention. Gastrointestinal adverse events were also more frequent in the semaglutide group.
03 / LIMITS
How should it be interpreted?
The result concerns the full trial setting, not a stand-alone material. The study does not separate every contribution of dietary support, counseling and drug treatment, and its population limits generalization.
Voltera Peptide editorial reading note. Based on the linked source record. Methods and corrections.